This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

PATIENT PROFILE 4Teenage competitive swimmer suffering with regular disease flares and itching​​​​​​​​​​​​​​Who is the patient?

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.​​​​​​​

  • ​​​​​​​Anglo-Chinese female, 14 years old
  • Disease and treatment history: Diagnosis of AD at age 12; prone to seasonal flares that are particularly itchy. Various approved treatments tried but lesions continue to worsen; treatments included topical corticosteroids for flare management, TCI (pimecrolimus 1% BID) and phototherapy
  • Clinical assessment: EASI=24; 40% BSA (primarily the torso and legs)
  • Personal impact: A competitive swimmer who trains daily (which may exacerbate her flares), she is very conscious of her lesions and is considering giving up the sport due to appearance-related bullying
  • Preferences: Severely needle-phobic, but her parents have indicated they could manage injections if absolutely necessary
Why consider Cibinqo (abrocitinib)?1. Significantly more patients achieved skin clearance at Week 12 with Cibinqo vs placebo1–3JADE TEEN (CO-PRIMARY ENDPOINTS, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)Proportion of patients achieving IGA 0/1 at Week 12
Scroll left to view table
IGA 0/1 at Week 12 no./Total no. (%, 95% CI)
Cibinqo 200 mg 43/93 (46.2%; 36.1–56.4)
Cibinqo 100 mg 37/89 (41.6%; 31.3–51.8)
Placebo 23/94 (24.5%; 15.8–33.2)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. 

Proportion of patients achieving EASI-75Example
Scroll left to view table
EASI-75 at Week 12 no./Total no. (%, 95% CI)
Cibinqo 200 mg 67/93 (72.0%; 62.9–81.2)
Cibinqo 100 mg 61/89 (68.5%; 58.9–78.2)
Placebo 39/94 (41.5%; 31.5–51.4)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. 

2. Significantly more patients achieved itch relief with Cibinqo vs placebo1–3JADE TEEN (KEY SECONDARY ENDPOINT, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)Proportion of patients achieving PP-NRS4
Scroll left to view table
PP-NRS4 at Week 12 n0./Total no. (%, 95% CI)
Cibinqo 200 mg 41/74 (55.4%; 44.1–66.7)
Cibinqo 100 mg 40/76 (52.6%; 41.4–63.9)
Placebo 25/84 (29.8%; 20.0–39.5)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.

3. Cibinqo helps reduce flares vs placebo*1,4JADE REGIMEN (PRIMARY ENDPOINT)Cumulative probability of patients experiencing a flare
Explore morePatient 1

Unemployed male with increasingly uncontrolled itching leading to sleep deprivation, weight gain and low self-esteem.

View profile​​​​​​​Loading
Patient 2

Middle-aged mother with uncontrolled, severe eczematous lesions, resulting in selfconsciousness and anxiety.

View profile​​​​​​​​​​​​​​Loading

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.​​​​​​​

*Flare defined as losing the IGA response (IGA ≥2) AND losing at least 50% of the EASI response obtained at Week 12 of the open-label induction phase. Following an open-label run-in period of 12 weeks in which patients received Cibinqo 200 mg OD, responders were randomised 1:1:1 to receive either Cibinqo 200 mg, Cibinqo 100 mg, or placebo.
This study included a 12-week induction period.

AD=atopic dermatitis; BID=twice daily; BSA=body surface area; CI​​​​​​​=confidence interval; EASI=Eczema Area and Severity Index; HR=hazard ratio; IGA=Investigator’s Global Assessment; LSM=least squares mean; NS=not significant; OD=once daily; OL=open label; PP-NRS=Peak Pruritus Numerical Rating Scale.

Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.Eichenfield L, et al. JAMA Dermatol 2021;doi:10.1001/jamadermatol.2021.2830.Eichenfield L, et al. JAMA Dermatol 2021;doi:10.1001/jamadermatol.2021.2830. Supplementary appendix 3Blauvelt A, et al. JAAD 2021; doi.org/10/1016/j.jaad.2021.05.075.
PP-CIB-GBR-0059. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​